4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The glucagon-like peptide 1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) which mediates the effects of GLP-1, an incretin hormone secreted primarily from L-cells in the intestine and within the central nervous system. The GLP-1R, upon activation, exerts several metabolic effects including the release of insulin and suppression of appetite, and has, accordingly, become an important target for the treatment for type 2 diabetes (T2D). Recently, there has been heightened interest in how the activated GLP-1R is trafficked between different endomembrane compartments, controlling the spatial origin and duration of intracellular signals. The discovery of “biased” GLP-1R agonists that show altered trafficking profiles and selective engagement with different intracellular effectors has added to the tools available to study the mechanisms and physiological importance of these processes. In this review we survey early and recent work that has shed light on the interplay between GLP-1R signalling and trafficking, and how it might be therapeutically tractable for T2D and related diseases.

          Related collections

          Most cited references116

          • Record: found
          • Abstract: found
          • Article: not found

          IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

          To produce current estimates of the national, regional and global impact of diabetes for 2015 and 2040.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Pathophysiology of Type 2 Diabetes Mellitus

            Type 2 Diabetes Mellitus (T2DM), one of the most common metabolic disorders, is caused by a combination of two primary factors: defective insulin secretion by pancreatic β-cells and the inability of insulin-sensitive tissues to respond appropriately to insulin. Because insulin release and activity are essential processes for glucose homeostasis, the molecular mechanisms involved in the synthesis and release of insulin, as well as in its detection are tightly regulated. Defects in any of the mechanisms involved in these processes can lead to a metabolic imbalance responsible for the development of the disease. This review analyzes the key aspects of T2DM, as well as the molecular mechanisms and pathways implicated in insulin metabolism leading to T2DM and insulin resistance. For that purpose, we summarize the data gathered up until now, focusing especially on insulin synthesis, insulin release, insulin sensing and on the downstream effects on individual insulin-sensitive organs. The review also covers the pathological conditions perpetuating T2DM such as nutritional factors, physical activity, gut dysbiosis and metabolic memory. Additionally, because T2DM is associated with accelerated atherosclerosis development, we review here some of the molecular mechanisms that link T2DM and insulin resistance (IR) as well as cardiovascular risk as one of the most important complications in T2DM.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Mechanisms of clathrin-mediated endocytosis

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                10 May 2021
                2021
                : 12
                : 678055
                Affiliations
                [1] 1 Section of Endocrinology and Investigative Medicine, Imperial College London , London, United Kingdom
                [2] 2 Section of Cell Biology and Functional Genomics, Imperial College London , London, United Kingdom
                Author notes

                Edited by: Peter Flatt, Ulster University, United Kingdom

                Reviewed by: Jonathan Campbell, Duke University, United States; Catherine Arden, Newcastle University, United Kingdom

                *Correspondence: Ben Jones, ben.jones@ 123456imperial.ac.uk ; Alejandra Tomas, a.tomas-catala@ 123456imperial.ac.uk

                This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2021.678055
                8143046
                34040588
                1a53b595-980b-4e87-b643-eb242654da4d
                Copyright © 2021 Marzook, Tomas and Jones

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 08 March 2021
                : 15 April 2021
                Page count
                Figures: 2, Tables: 0, Equations: 0, References: 116, Pages: 12, Words: 6056
                Funding
                Funded by: Medical Research Council 10.13039/501100000265
                Funded by: Biotechnology and Biological Sciences Research Council 10.13039/501100000268
                Funded by: NIHR Imperial Biomedical Research Centre 10.13039/501100013342
                Funded by: Diabetes UK 10.13039/501100000361
                Funded by: Society for Endocrinology 10.13039/501100000382
                Funded by: British Society for Neuroendocrinology 10.13039/100014669
                Funded by: European Foundation for the Study of Diabetes 10.13039/501100001648
                Funded by: Medical Research Council 10.13039/501100000265
                Categories
                Endocrinology
                Review

                Endocrinology & Diabetes
                glp-1,glp-1r,biased agonism,receptor trafficking,pancreatic beta cells
                Endocrinology & Diabetes
                glp-1, glp-1r, biased agonism, receptor trafficking, pancreatic beta cells

                Comments

                Comment on this article